Lipella Pharmaceuticals Inc. products

Hemorrhagic Cystitis, also called Radiation Cystitis when occurring after pelvic radiation. Lipella is currently conducting a phase-2a, dose-escalation clinical trial evaluating LP-10 (liposomal tacrolimus) for the treatment of hemorrhagic cystitis. Lipella has received US-FDA Orphan Designation for this developmental product. Radiation used to treat prostate, colon, uterine, cervical and other pelvic cancers can cause chronic, painful urinary inflammation and blood loss called hemorrhagic cystitis. The blood loss, associated with hemorrhagic cystitis and radiation cystitis can lead to surgery, and can be fatal.

The following is a link to the Radiation Cystitis Patient Registry. If you are a cancer survivor with a history of pelvic radiation therapy, please consider joining the registry. The potential uses of this registry about radiation cystitis and hemorrhagic cystitis (and cancer survivorship post-radiotherapy) include: improving the scientific understanding of radiation cystitis, discovering trends and common needs of registry participants, describing the aggregate personal characteristics of radiation cystitis patients within the registry, documenting registry patient medical histories, and contacting radiation cystitis registry participants to inform them of new studies. This registry has been created and developed within the published guidance of the National Institute of Health Rare Diseases Registry Program (RaDaR).